# DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Source: https://onco.cc/trials/nct06176261/  
OnCo record `nct06176261` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of datopotamab deruxtecan in triple-negative breast cancer, run by Nancy Lin, MD, now recruiting.

## Summary

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs is a phase 2, interventional study registered as NCT06176261 by Nancy Lin, MD, with a registry enrolment figure of 58 participants, started 2024-01-08 and due to reach its primary completion in 2028-01-01. Interventions recorded: Datopotamab Deruxtecan. Conditions listed: Breast Cancer; Breast Cancer Female; Metastatic Triple-Negative Breast Carcinoma; ER Positive Breast Cancer; HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma; ER-negative Breast Cancer. Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06176261
- Phase: 2
- Setting: DATO-BASE: A Phase 2 Trial of DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
- Sponsor: Nancy Lin, MD
- Enrolled: 58

## Sources

- ClinicalTrials.gov NCT06176261: https://clinicaltrials.gov/study/NCT06176261

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- terms: [Brain metastases (intracranial disease)](https://onco.cc/terms/brain-metastases/), [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/)

---
JSON: https://onco.cc/api/v1/entities/nct06176261.json